Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. (Q37277077)

19 August 2017

1 reference

title

Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. (English)

1 reference

19 August 2017

1 reference

1 reference

Jean-François Rossignol

series ordinal

1

1 reference

PubMed ID

18811238

19 August 2017

Emmet B Keeffe

series ordinal

2

1 reference

19 August 2017

1 October 2008

1 reference

19 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

19 August 2017

3

1 reference

19 August 2017

539-545

1 reference

19 August 2017

5

1 reference

Nitazoxanide: a review of its use in the treatment of gastrointestinal infections

19 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Nitazoxanide: a new thiazolide antiparasitic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Nitazoxanide: a new broad spectrum antiparasitic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

In-vitro transfer of nitazoxanide across the intestinal epithelial barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.5.539

21 January 2018

Identifiers

DOI

10.2217/17460913.3.5.539

1 reference

19 August 2017

1 reference

PubMed ID

18811238